2011
DOI: 10.2174/092986711796504646
|View full text |Cite
|
Sign up to set email alerts
|

Nitric Oxide and Cyclic GMP Signaling Pathway as a Focus for Drug Development

Abstract: Recent progress in understanding of the nitric oxide and cGMP signaling pathway provided evidence for mechanism of action of known drugs and identified novel targets for drug development. These discoveries resulted in numerous efforts in drug and formulation discovery. Some of the most promising approaches were applied for efficient therapies of various diseases.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

0
18
0
3

Year Published

2013
2013
2015
2015

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 25 publications
(21 citation statements)
references
References 62 publications
0
18
0
3
Order By: Relevance
“…Although the sGC heme normally functions in its reduced (ferrous) oxidation state, an increase in cell oxidant stress that can occur under many inflammatory conditions (7) can cause oxidation and loss of the sGC heme, thus creating a population of heme-free (apo) sGC that is insensitive to NO (8,9). This led to development of novel drug candidates that can activate sGC independent of NO or its heme (10,11) and has piqued interest in the cellular mechanisms that control the heme content, protein associations, and activity of sGC.…”
Section: Soluble Guanylyl Cyclase (Sgc)mentioning
confidence: 99%
“…Although the sGC heme normally functions in its reduced (ferrous) oxidation state, an increase in cell oxidant stress that can occur under many inflammatory conditions (7) can cause oxidation and loss of the sGC heme, thus creating a population of heme-free (apo) sGC that is insensitive to NO (8,9). This led to development of novel drug candidates that can activate sGC independent of NO or its heme (10,11) and has piqued interest in the cellular mechanisms that control the heme content, protein associations, and activity of sGC.…”
Section: Soluble Guanylyl Cyclase (Sgc)mentioning
confidence: 99%
“…Azot-monoksid učestvuje u regulaciji različitih bioloških procesa u organizmu. Mehanizmi delovanja NO obuhvataju: aktivaciju solubilne gvanilat ciklaze i stvaranje cikličnog guanozin-monofosfata, vezivanje sa hem grupama u drugim enzimima, formiranje peroksinitritnog anjona u reakciji sa superoksidnim anjonom, i nitrozilaciju proteina, lipida i nukleinskih kiselina (3,4 …”
Section: Uvodunclassified
“…Azot-monoksid učestvuje u regulaciji različitih bioloških procesa u organizmu. Mehanizmi delovanja NO obuhvataju: aktivaciju solubilne gvanilat ciklaze i stvaranje cikličnog guanozin-monofosfata, vezivanje sa hem grupama u drugim enzimima, formiranje peroksinitritnog anjona u reakciji sa superoksidnim anjonom, i nitrozilaciju proteina, lipida i nukleinskih kiselina (3,4 Nadbuburežna žlezda kao deo hipotalamo-hipofiznonadbubrežne (HPA) osovine i simpatoadrenalnog sistema reguliše odgovor organizma na različite stresore. Nervni impulsi, hormonsko i citokinsko delovanje integrišu se na nivou hipotalamusa odakle se putem kortikotropin oslobađajućeg hormona i arginin-vasopresina utiče na aktivnost adenohipofize.…”
Section: Uvodunclassified
“…Soluble guanylyl cyclase (sGC) is activated by nitric oxide (NO) and plays an important role in the regulation of cardiovascular and neuronal functions (Friebe and Koesling, 2009;Kots et al, 2011;Derbyshire and Marletta, 2012). Binding of NO to the heme moiety of the enzyme induces a conformational change so that sGC then effectively catalyzes the conversion of GTP into the second messenger cGMP (Friebe and Koesling, 2009;Kots et al, 2011;Derbyshire and Marletta, 2012).…”
Section: Introductionmentioning
confidence: 99%
“…Binding of NO to the heme moiety of the enzyme induces a conformational change so that sGC then effectively catalyzes the conversion of GTP into the second messenger cGMP (Friebe and Koesling, 2009;Kots et al, 2011;Derbyshire and Marletta, 2012). NO-containing drugs are used clinically to improve symptoms in coronary heart disease (Daiber et al, 2010).…”
Section: Introductionmentioning
confidence: 99%